JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB24935

FITC荧光Anti-CTLA4抗体[1B8]

FITC Anti-CTLA4 antibody [1B8]

Be the first to review this product! Submit a review

|

(2 Publications)

Armenian hamster Monoclonal CTLA4 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Mouse samples. Cited in 2 publications. Immunogen corresponding to Native Full Length Protein corresponding to Human CTLA4.

查看别名

CD152, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4

1 Images
Flow Cytometry - FITC Anti-CTLA4 antibody [1B8] (AB24935)
  • Flow Cyt

Unknown

Flow Cytometry - FITC Anti-CTLA4 antibody [1B8] (AB24935)

Flow cytometry analysis staining CTLA4 in mouse splenocytes using ab24935 at a dilution of 1 ug/106 cells. Hamster anti-mouse CD152-FITC was used as an isotype control.

关键信息

宿主种属

Armenian hamster

克隆

Monoclonal

克隆号

1B8

亚型

IgG

偶联物

FITC

激发波长/发射波长

Ex: 495nm, Em: 519nm

不含载体蛋白

No

反应种属

Mouse

应用

Flow Cyt

applications

免疫原

Native Full Length Protein corresponding to Human CTLA4.

P16410

特异性

ab24935 recognises mouse CD152/CTLA-4

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "3 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/products/primary-antibodies/fitc-armenian-hamster-igg-monoclonal-htk888-isotype-control-ab18473'>ab18473</a> - Armenian Hamster monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>" } } }

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification
存储溶液
pH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS
运输条件
Blue Ice
推荐的短期储存条件
+4°C
推荐的长期储存条件
+4°C
储存信息
Store in the dark

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

CTLA-4 also known as CD152 is an immune checkpoint receptor with a molecular weight of approximately 34 kDa. This protein is expressed on the surface of T-cells especially after activation and sometimes on regulatory T-cells (Tregs). CTLA-4 competes with CD28 for binding to the same ligands CD80 and CD86 on antigen-presenting cells. Unlike CD28 which stimulates T-cell activation CTLA-4 sends inhibitory signals to downregulate immune responses. By doing this CTLA-4 helps maintain immune system homeostasis and prevents autoimmune reactions.
Biological function summary

The CTLA-4 protein functions as a critical regulator of the immune system. It interacts with CD80/CD86 in a complex that effectively transmits inhibitory signals to T-cells. CTLA-4 controls the amplitude of the initial activation of T-cells ensuring that the body's immune responses are kept under control. In regulatory T-cells CTLA-4 engagement contributes to their immunosuppressive functions through which they maintain tolerance to self-antigens and prevent overactive immune reactions.

Pathways

CTLA-4 involves itself in the adaptive immune response pathways specifically the regulation of T-cell activity. CTLA-4's interaction with CD80/CD86 modulates pathways associated with TCR (T-cell receptor) signaling. When CTLA-4 binds its ligands it recruits phosphatases such as SHP-2 that dephosphorylate signaling proteins leading to the downregulation of T-cell interaction. This pathway interaction exemplifies how CTLA-4 acts in concert with proteins like CD28 to finely tune immune responses.

CTLA-4 plays a role in autoimmune diseases and cancer. The dysregulation of CTLA-4 function can lead to autoimmune disorders where the immune system attacks the body's own tissue. In cancer tumor cells may manipulate CTLA-4 pathways to evade immune surveillance. Targeted therapies like anti-CTLA-4 antibodies such as ipilimumab have been developed to block CTLA-4 aiming to enhance the immune system’s ability to attack cancer cells. These treatments highlight the role of CTLA-4 in balancing immune activity and the potential to alter this balance for therapeutic benefit.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
See full target information CTLA4

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Molecular medicine reports 20:4303-4314 PubMed31545427

2019

MicroRNA‑30a controls the instability of inducible CD4+ Tregs through SOCS1.

Applications

Unspecified application

Species

Unspecified reactive species

Ya Zhou,Yongju Li,Jia Lu,Xiaowu Hong,Lin Xu

International immunology 21:1065-77 PubMed19651643

2009

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Applications

Unspecified application

Species

Unspecified reactive species

Wenshi Wang,Roy Lau,Daohai Yu,Weiwei Zhu,Alan Korman,Jeffrey Weber
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com